ANNALS OF NEUROLOGY, vol.76, no.2, pp.231-240, 2014 (SCI-Expanded)
Objective: To identify a biomarker distinguishing patients who, despite a primary progressive multiple sclerosis (PPMS) clinical course, may nonetheless benefit from immune therapy.